Regenerating Beta Cells by Lineage Reprogramming

通过谱系重编程再生β细胞

基本信息

  • 批准号:
    8522193
  • 负责人:
  • 金额:
    $ 69.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-15 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Lineage reprogramming, whereby cells of adult organs are converted from one specialized cell type into another, has emerged in recent years as a promising approach to regenerate cells lost due to disease or injury. This regenerative approach could prove valuable for the treatment of Type 1 diabetes where insulin secreting ¿-cells are destroyed by autoimmune attacks. The long-term goal of this proposal is to devise strategies to reprogram adult cells of endodermal organs into pancreatic ?-cells for cell replacement therapies. In a recent study, our research groups showed that pancreatic exocrine cells can be reprogrammed into insulin secreting ?-cells in adult animals by a combination of three transcription factors. We propose to expand on this study and build a set of new tools to investigate the mechanisms of reprogramming and study the reprogramming of several related endodermal cell types, including pancreatic exocrine cells, liver cells and intestine cells, into ¿-cells. In Specific Aim I, we will develop a new generation of viral vectors to dissect the molecular and epigenetic mechanisms of in vivo reprogramming of exocrine cells into ?-cells. In Specific Aim II, we will develop inducible mouse genetic models to investigate the in vivo reprogramming of adult endodermal cells to ?-cells. In Specific Aim III, we will use chemical and genetic screens to reprogram hepatocytes to ?-cells ex vivo. Together, these studies are expected to yield important insights into the mechanism of ?-cell reprogramming and help define additional cell types and reprogramming methodologies to regenerate ?-cells in the adult. Such tools and knowledge will form the foundation for developing novel cell replacement therapies for Type 1 diabetes. PUBLIC HEALTH RELEVANCE: Our proposed studies are broadly aimed at developing novel cell replacement therapies for pancreatic ?-cells in order to treat type 1 diabetes. Specifically, we will develop new research tools to define the cell types and conditions whereby cells of pancreas, liver, and intestine can be converted into functional ?-cells.
描述(由申请人提供):谱系重编程,即成年器官的细胞从一种专门的细胞类型转化为另一种细胞类型,近年来已成为再生因疾病或损伤而丢失的细胞的有希望的方法。这种再生方法可能被证明对治疗1型糖尿病有价值,在这种糖尿病中,胰岛素分泌细胞被自身免疫攻击破坏。这项提案的长期目标是设计策略,将内胚层器官的成体细胞重新编程为胰腺?用于细胞替代疗法。在最近的一项研究中,我们的研究小组表明,胰腺外分泌细胞可以重新编程为胰岛素分泌细胞。在成年动物的细胞中通过三种转录因子的组合。我们建议扩展这项研究,并建立一套新的工具来研究重编程的机制,并研究几种相关的内胚层细胞类型(包括胰腺外分泌细胞,肝细胞和肠细胞)重编程为?细胞。 在特定目标I中,我们将开发新一代病毒载体,以剖析外分泌细胞在体内重编程为?细胞在特定目标II中,我们将开发诱导型小鼠遗传模型,以研究成体内胚层细胞在体内重编程为?细胞在特定目标III中,我们将使用化学和遗传筛选将肝细胞重编程为?离体细胞。总之,这些研究预计将产生重要的见解?细胞重编程和帮助定义额外的细胞类型和重编程方法再生?成人的细胞。这些工具和知识将成为开发1型糖尿病新型细胞替代疗法的基础。 公共卫生相关性:我们提出的研究广泛旨在开发用于胰腺癌的新型细胞替代疗法。1型糖尿病的治疗方法具体而言,我们将开发新的研究工具,以确定胰腺,肝脏和肠道细胞可以转化为功能性细胞的细胞类型和条件。细胞

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DOUGLAS A MELTON其他文献

DOUGLAS A MELTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DOUGLAS A MELTON', 18)}}的其他基金

Biomarkers for Diabetes Using Stem Cell-Derived Beta Cells
使用干细胞衍生的 β 细胞作为糖尿病生物标志物
  • 批准号:
    8813227
  • 财政年份:
    2014
  • 资助金额:
    $ 69.12万
  • 项目类别:
Islet on a Chip
芯片上的胰岛
  • 批准号:
    8813382
  • 财政年份:
    2014
  • 资助金额:
    $ 69.12万
  • 项目类别:
Reconstruction of Human Type 1 Diabetes in Mice
在小鼠中重建人类 1 型糖尿病
  • 批准号:
    8183478
  • 财政年份:
    2011
  • 资助金额:
    $ 69.12万
  • 项目类别:
Regenerating Beta Cells by Lineage Reprogramming
通过谱系重编程再生β细胞
  • 批准号:
    8316302
  • 财政年份:
    2010
  • 资助金额:
    $ 69.12万
  • 项目类别:
Regenerating Beta Cells by Lineage Reprogramming
通过谱系重编程再生β细胞
  • 批准号:
    8717645
  • 财政年份:
    2010
  • 资助金额:
    $ 69.12万
  • 项目类别:
Regenerating Beta Cells by Lineage Reprogramming
通过谱系重编程再生β细胞
  • 批准号:
    7993955
  • 财政年份:
    2010
  • 资助金额:
    $ 69.12万
  • 项目类别:
Regenerating Beta Cells by Lineage Reprogramming
通过谱系重编程再生β细胞
  • 批准号:
    8466013
  • 财政年份:
    2010
  • 资助金额:
    $ 69.12万
  • 项目类别:
Regenerating Beta Cells by Lineage Reprogramming
通过谱系重编程再生β细胞
  • 批准号:
    8143353
  • 财政年份:
    2010
  • 资助金额:
    $ 69.12万
  • 项目类别:
Identification of Genes and Compounds That Control Beta Cell Replication
控制β细胞复制的基因和化合物的鉴定
  • 批准号:
    8044507
  • 财政年份:
    2010
  • 资助金额:
    $ 69.12万
  • 项目类别:
Pancreatic Islet Design & Engineering (SysCODE 3 of 10)
胰岛设计
  • 批准号:
    8070896
  • 财政年份:
    2007
  • 资助金额:
    $ 69.12万
  • 项目类别:

相似海外基金

cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
cGAS-STING 通路靶向具有 CD46 趋向性和 AFP 启动子的复制腺病毒条件性复制限制用于治疗肝细胞癌
  • 批准号:
    10436626
  • 财政年份:
    2021
  • 资助金额:
    $ 69.12万
  • 项目类别:
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10557162
  • 财政年份:
    2021
  • 资助金额:
    $ 69.12万
  • 项目类别:
Molecular therapy of replication-competent adenoviruses targeting characteristic gene mutations found in mesothelioma
针对间皮瘤中发现的特征基因突变的具有复制能力的腺病毒的分子疗法
  • 批准号:
    21K08199
  • 财政年份:
    2021
  • 资助金额:
    $ 69.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10330464
  • 财政年份:
    2021
  • 资助金额:
    $ 69.12万
  • 项目类别:
Structural characterization of nucleoprotein cores of human adenoviruses
人腺病毒核蛋白核心的结构表征
  • 批准号:
    9807741
  • 财政年份:
    2019
  • 资助金额:
    $ 69.12万
  • 项目类别:
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2018
  • 资助金额:
    $ 69.12万
  • 项目类别:
    Discovery Grants Program - Individual
The therapeutic strategies with augmented replications of oncolytic adenoviruses for malignant mesothelioma
溶瘤腺病毒增强复制治疗恶性间皮瘤的治疗策略
  • 批准号:
    18K15937
  • 财政年份:
    2018
  • 资助金额:
    $ 69.12万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2017
  • 资助金额:
    $ 69.12万
  • 项目类别:
    Discovery Grants Program - Individual
Exploring the effects of nutrient deprivation on T cells and oncolytic adenoviruses, in order to create immune activators for tumour therapy
探索营养剥夺对 T 细胞和溶瘤腺病毒的影响,以创造用于肿瘤治疗的免疫激活剂
  • 批准号:
    1813152
  • 财政年份:
    2016
  • 资助金额:
    $ 69.12万
  • 项目类别:
    Studentship
Research on detection of novel adenoviruses by genetic methods
新型腺病毒的基因检测研究
  • 批准号:
    16K09118
  • 财政年份:
    2016
  • 资助金额:
    $ 69.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了